QIAGEN (QGEN)
(Delayed Data from NYSE)
$44.05 USD
+0.29 (0.66%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $44.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.05 USD
+0.29 (0.66%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $44.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.
Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 3.13% and 0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe
by Zacks Equity Research
QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.
Genomics Market Gains Momentum: 3 DNA Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
by Zacks Equity Research
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Why Is QIAGEN (QGEN) Up 13.8% Since Its Last Earnings Report?
by Zacks Equity Research
QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.
QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.
Why QIAGEN (QGEN) Might Surprise This Earnings Season
by Zacks Equity Research
QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening
by Zacks Equity Research
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform
by Zacks Equity Research
QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.
5 Reasons Why You Should Add Becton, Dickinson (BDX) Now
by Zacks Equity Research
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
QIAGEN's QFT-Plus Approval in Japan to Expand Customer Base
by Zacks Equity Research
QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.
QIAGEN Strong on Molecular Diagnostics, Competition Rife
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.
QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.
FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic
by Zacks Equity Research
QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.
Abbott Boosts Diagnostics Arm With Alinity H-Series Launch
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.
QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.
QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View
by Zacks Equity Research
QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.
Should You Sell QIAGEN (QGEN) Before Earnings?
by Zacks Equity Research
QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.
Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe
by Zacks Equity Research
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.